Benzinga··NaHemab Therapeutics Prices $346.7M IPO as Blood Disorder Biotech Debuts on Nasdaq
Hemab Therapeutics raised $346.7M in upsized IPO, pricing 19.3M shares at $18 with full underwriter exercise.
COAGIPOclinical-stage
clinical-stage
39 articlesBenzinga··Na
Benzinga··Sweta KillaSeaport Therapeutics Eyes Nasdaq Debut With $255M IPO, Signaling Biotech Sector Momentum
Seaport Therapeutics raised $255 million through IPO priced at $18/share, beginning Nasdaq trading Friday as ticker $SPTX, amid growing biotech IPO momentum.
SFTBYAVEXXEIPObiotech
GlobeNewswire Inc.··NaHemab Therapeutics Prices $301.5M IPO at $18/Share, Nasdaq Debut Set for May
Hemab Therapeutics prices $301.5M IPO at $18/share, listing on Nasdaq as $COAG starting May 1, 2026.
JEFEVRIPOclinical-stage
GlobeNewswire Inc.··NaVaccinex Advances Alzheimer's Pipeline as Clinical-Stage Biotech Initiates Phase 2b Study
Vaccinex released 2025 financial results while launching Phase 2b Alzheimer's study, advancing its antibody therapy pipeline for neurodegenerative diseases and cancer.
VCNXfinancial resultsclinical-stage
GlobeNewswire Inc.··Not SpecifiedTaysha Gene Therapies to Report Q1 2026 Results, Discuss Clinical Pipeline Progress
Taysha Gene Therapies will report Q1 2026 financial results and discuss TSHA-102 Rett syndrome program progress on May 6, 2026.
TSHAclinical-stagegene therapy
GlobeNewswire Inc.··NaOruka Therapeutics Raises $700M in Upsized Public Offering at $72.50 Per Share
Oruka Therapeutics prices 9.66M shares at $72.50 in upsized offering, raising $700.4M with potential additional proceeds from underwriter overallotment option.
ORKAmonoclonal antibodyclinical-stage
The Motley Fool··Eric VolkmanCelcuity Surges on Bullish Cancer Drug Outlook as Analyst Initiates Coverage
Celcuity rises 4% after Citizens initiates 'market outperform' coverage with $150 price target, citing gedatolisib's breast cancer approval potential within two months and multi-indication opportunity.
CELCFDA approvalbiotech
GlobeNewswire Inc.··Not SpecifiedEvaxion Consolidates Leadership, Promotes Rønø to Dual CSO-COO Role
Evaxion promotes Birgitte Rønø to combined Chief Scientific and Chief Operating Officer role to enhance platform communication and operational execution.
EVAXclinical-stageAI-Immunology platform
The Motley Fool··Andy GouldKopp Family Office Dumps $3.5M Viridian Stake as Biotech Stock Tanks 50%
Kopp Family Office exits $3.5M Viridian stake as stock plummets 50% following disappointing Phase 3 data and Amgen's superior competing results.
AMGNVEAVRDNAGGFDA approvalbiotech
The Motley Fool··Cory RenauerDianthus CFO Sells $739K in Stock as Biotech Eyes Phase 3 Success
Dianthus Therapeutics CFO Ryan Savitz sold 8,224 shares for $739,000 on April 9, 2026, reducing direct holdings to zero while retaining substantial options.
DNTHmonoclonal antibodybiotech
Benzinga··NaTrevi Therapeutics Prices $150M Stock Offering as It Advances Chronic Cough Treatment
Trevi Therapeutics raises $150M via stock offering at $13/share to fund development of Haduvio for idiopathic pulmonary fibrosis-related cough.
TRVIstock offeringclinical-stage
GlobeNewswire Inc.··NaTrevi Therapeutics Raises $150M to Advance Nalbuphine Program for Chronic Cough
Trevi Therapeutics prices $150M stock offering at $13/share, raising capital for Haduvio development across chronic cough indications.
TRVIclinical-stagepublic offering
The Motley Fool··Pamela KockNuvation Bio Executive Liquidates $904K in Stock; Retains Substantial Position
Nuvation Bio's Chief Regulatory Officer sold 200,000 shares for $904K but retained 53,000 shares and 700,000 options, suggesting routine profit-taking rather than lost confidence.
NUVBbiotechclinical-stage
GlobeNewswire Inc.··Oric Pharmaceuticals, Inc.ORIC Pharma Awards Equity Grants to New Hire Under Nasdaq Rule 5635
ORIC Pharmaceuticals granted 80,000 options and 15,000 RSUs to new hire under Nasdaq Rule 5635(c)(4), reflecting ongoing biotech talent competition.
ORICclinical-stagerestricted stock units
The Motley Fool··Jonathan PoncianoPalvella Stock Soars 340% as COO Executes Pre-Planned Share Sale
Palvella COO sells ~$508K in shares via pre-planned trading arrangement amid 340% annual surge, driven by strong Phase 3 QTORIN rapamycin data and upcoming NDA submission.
PVLAbiotechclinical-stage
GlobeNewswire Inc.··NaApogee Therapeutics Raises $350M via Public Offering to Fuel Biotech Pipeline
Apogee Therapeutics prices $350M offering at $70/share to fund development of inflammatory disease treatments, with lead candidate Zumilokibart targeting atopic dermatitis.
APGEclinical-stagepublic offering
The Motley Fool··Jonathan PoncianoBiohaven Stock Crashes 70%, but $6M Insider Bet Hints at Turnaround Play
Sarissa Capital deploys $5.79M in beaten-down biotech Biohaven despite 70% stock decline, betting on upcoming late-stage trial data and obesity candidate.
CYTKBHVNNBIXstock declineFDA rejection
The Motley Fool··Jonathan PoncianoBoone Capital Exits 372% Biotech Winner to Chase Emerging Clinical Plays
Boone Capital liquidates entire $13.57M Cogent Biosciences stake despite 372% gain, reallocating to earlier-stage biotech plays like TYRA. Strategic rebalancing in volatile sector.
MDTTYRAIONSCOGTBMRN+2biotechclinical-stage
The Motley Fool··James HalleyTwo Biotech Darlings Poised for Acquisition: Abivax and Nektar Signal M&A Targets
Abivax and Nektar Therapeutics are positioned as acquisition targets with promising drug candidates and upcoming phase 3 trial data, attracting interest from major pharmaceutical companies.
AMGNABBVLLYAZNABVX+1acquisitionbiotech
Benzinga··Gav BlaxbergEdgewise Therapeutics' $3.1B Bet on Two Blockbuster Drug Candidates
Edgewise Therapeutics pursues two major drug candidates addressing unmet cardiac and muscular disease needs, with pivotal data expected through 2026.
BMYCELGrALNYEWTXFDA approvalbiotech